Menu Search
Equities

Fresh2 Group Ltd

0UC0:FRA

Fresh2 Group Ltd

Actions
  • Price (EUR)1.80
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-56.10%
  • Beta--
Data delayed at least 15 minutes, as of Sep 26 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fresh2 Group Ltd, formerly AnPac Bio-Medical Science Co Ltd, is a biotechnology company mainly engaged in early cancer screening and detection. The Company is engaged in marketing and selling multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. The Company's CDA technology also assists physicians in cancer diagnosis, prognosis and recurrence. The Company provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, Internet, and Web3 transformation of start-ups and traditional enterprises.

  • Revenue in USD (TTM)1.63m
  • Net income in USD-13.47m
  • Incorporated2010
  • Employees75.00
  • Location
    Fresh2 Group Ltd801 Bixing Street, Bihu CountyLishui F4 323006ChinaCHN
  • Phone+86 57 820516666
  • Websitehttp://www.anpac.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.